Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2014 1
2015 10
2016 48
2017 78
2018 116
2019 195
2020 332
2021 531
2022 541
2023 516
2024 603
2025 588
2026 242

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,313 results

Results by year

Citations

4 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials.
Carvalho PEP, Veiga TMA, Simões E Silva AC, Gewehr DM, Dagostin CS, Fernandes A, Nasi G, Cardoso R. Carvalho PEP, et al. Clin Res Cardiol. 2023 Aug;112(8):1044-1055. doi: 10.1007/s00392-022-02148-2. Epub 2023 Jan 2. Clin Res Cardiol. 2023. PMID: 36592186 Free PMC article.
BACKGROUND: We sought to compare cardiovascular outcomes, renal function, and diuresis in patients receiving standard diuretic therapy for acute heart failure (AHF) with or without the addition of SGLT2i. ...The addition of SGLT2i to conventional therapy for …
BACKGROUND: We sought to compare cardiovascular outcomes, renal function, and diuresis in patients receiving standard diuretic therap …
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. Voors AA, et al. Nat Med. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28. Nat Med. 2022. PMID: 35228754 Free PMC article. Clinical Trial.
The sodium-glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when in …
The sodium-glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure …
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. Zannad F, et al. Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30. Lancet. 2020. PMID: 32877652
BACKGROUND: Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced (assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) inhibition reduced the combined risk of cardiovascular death or hospitalisation for heart failure …
BACKGROUND: Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced (assessing empagliflozin) trials showed that sodium-glucose co-transp …
Kidney and heart failure outcomes associated with SGLT2 inhibitor use.
van der Aart-van der Beek AB, de Boer RA, Heerspink HJL. van der Aart-van der Beek AB, et al. Nat Rev Nephrol. 2022 May;18(5):294-306. doi: 10.1038/s41581-022-00535-6. Epub 2022 Feb 10. Nat Rev Nephrol. 2022. PMID: 35145275 Review.
After observations that sodium-glucose co-transporter 2 (SGLT2) inhibitors - originally developed as glucose-lowering agents - improved cardiovascular and renal outcomes in patients with type 2 diabetes, dedicated trials were initiated to evaluate the cardiovascu …
After observations that sodium-glucose co-transporter 2 (SGLT2) inhibitors - originally developed as glucose-lowering agents - improv …
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.
Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, Khariton Y, Malik AO, Khumri T, Umpierrez G, Lamba S, Sharma K, Khan SS, Chandra L, Gordon RA, Ryan JJ, Chaudhry SP, Joseph SM, Chow CH, Kanwar MK, Pursley M, Siraj ES, Lewis GD, Clemson BS, Fong M, Kosiborod MN. Nassif ME, et al. Nat Med. 2021 Nov;27(11):1954-1960. doi: 10.1038/s41591-021-01536-x. Epub 2021 Oct 28. Nat Med. 2021. PMID: 34711976 Free PMC article. Clinical Trial.
Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may i …
Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, …
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
Jhund PS. Jhund PS. Heart Fail Clin. 2022 Oct;18(4):579-586. doi: 10.1016/j.hfc.2022.03.010. Heart Fail Clin. 2022. PMID: 36216487 Free article. Review.
The trials of SLGT2 inhibitors in type 2 diabetes suggested a potential benefit of these drugs in patients with heart failure. When randomized trials confirmed their benefit in heart failure with reduced ejection fraction, attention turned to heart …
The trials of SLGT2 inhibitors in type 2 diabetes suggested a potential benefit of these drugs in patients with heart failure. …
Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.
Vaduganathan M, Claggett BL, Kulac IJ, Miao ZM, Desai AS, Jhund PS, Henderson AD, Brinker M, Lay-Flurrie J, Viswanathan P, Scheerer MF, Lage A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD. Vaduganathan M, et al. Circulation. 2025 Jan 14;151(2):149-158. doi: 10.1161/CIRCULATIONAHA.124.072055. Epub 2024 Sep 28. Circulation. 2025. PMID: 39340828 Free PMC article. Clinical Trial.
BACKGROUND: Patients with heart failure (HF) with mildly reduced or preserved ejection fraction face heightened long-term risks of morbidity and mortality. ...METHODS: FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients W …
BACKGROUND: Patients with heart failure (HF) with mildly reduced or preserved ejection fraction face heightened long-term risk …
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Vallon V, Verma S. Vallon V, et al. Annu Rev Physiol. 2021 Feb 10;83:503-528. doi: 10.1146/annurev-physiol-031620-095920. Epub 2020 Nov 16. Annu Rev Physiol. 2021. PMID: 33197224 Free PMC article. Review.
SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients with or without type 2 diabetes and preserved or reduced kidney function from failing. ...SGLT2 inhibitors are proximal tubule and osmotic diuretics that reduce volume …
SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients with or without type 2 diabetes an …
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Nuffield Department of Population Health Renal Studies Group, et al. Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016/S0140-6736(22)02074-8. Epub 2022 Nov 6. Lancet. 2022. PMID: 36351458 Free PMC article.
BACKGROUND: Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure or chronic kidney disease, or with type 2 diabetes and high risk of …
BACKGROUND: Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and …
Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure.
Modzelewski KL, Pipilas A, Bosch NA. Modzelewski KL, et al. JAMA Netw Open. 2024 May 1;7(5):e249305. doi: 10.1001/jamanetworkopen.2024.9305. JAMA Netw Open. 2024. PMID: 38696170 Free PMC article.
IMPORTANCE: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to have benefits when used in patients with heart failure. ...Eligible patients had a diagnosis of heart failure, had never received an SGLT2 inhibitor p …
IMPORTANCE: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to have benefits when used in patients with heart …
3,313 results